Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
Eur Arch Otorhinolaryngol. 2024 Aug;281(8):4175-4182. doi: 10.1007/s00405-024-08601-4. Epub 2024 Apr 5.
To determine the natural history of hearing loss and tumor volume in patients with untreated neurofibromatosis type 2 (NF2)-related schwannomatosis. Moreover, we statistically examined the factors affecting hearing prognosis.
This retrospective cohort study was conducted on 37 ears of 24 patients with NF2-related vestibular schwannomatosis followed up without treatment for more than 1 year. We obtained detailed chronological changes in the PTA and tumor volume in each case over time, and the rate of change per year was obtained. Multivariate analysis was also conducted to investigate factors associated with changes in hearing.
The average follow-up period was approximately 9 years, and hearing deteriorated at an average rate of approximately 4 dB/year. The rate of maintaining effective hearing decreased from 30 ears (81%) at the first visit to 19 ears (51%) at the final follow-up. The average rate of change in tumor growth for volume was approximately 686.0 mm/year. This study revealed that most patients with NF2 experienced deterioration in hearing acuity and tumor growth during the natural course. A correlation was observed between an increase in tumor volume and hearing loss (r = 0.686; p < 0.001).
Although the hearing preservation rate in NF2 cases is poor with the current treatment methods, many cases exist in which hearing acuity deteriorates, even during the natural course. Patients with an increased tumor volume during the follow-up period were more likely to experience hearing deterioration. Trial registration number 20140242 (date of registration: 27 October 2014).
确定未经治疗的神经纤维瘤病 2 型(NF2)相关施万细胞瘤患者听力损失和肿瘤体积的自然病程。此外,我们还对影响听力预后的因素进行了统计学检查。
本回顾性队列研究纳入了 24 例 NF2 相关前庭神经鞘瘤患者的 37 只耳朵,这些患者未经治疗且随访时间超过 1 年。我们获得了每个病例在时间上的 PTA 和肿瘤体积的详细时间变化,并获得了每年的变化率。还进行了多变量分析,以调查与听力变化相关的因素。
平均随访期约为 9 年,听力每年平均恶化约 4dB。有效听力保持率从首次就诊时的 30 只耳朵(81%)下降至最后一次随访时的 19 只耳朵(51%)。肿瘤体积生长的平均变化率约为 686.0mm/年。本研究表明,大多数 NF2 患者在自然病程中会出现听力敏感度下降和肿瘤生长。肿瘤体积增加与听力损失之间存在相关性(r=0.686;p<0.001)。
尽管目前的治疗方法对 NF2 患者的听力保留率较差,但在自然病程中仍有许多患者听力恶化。在随访期间肿瘤体积增加的患者更有可能出现听力下降。注册号 20140242(注册日期:2014 年 10 月 27 日)。